PMID- 19561450
OWN - NLM
STAT- MEDLINE
DCOM- 20090818
LR  - 20220318
IS  - 1532-0979 (Electronic)
IS  - 0147-5185 (Linking)
VI  - 33
IP  - 8
DP  - 2009 Aug
TI  - Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the 
      diagnosis of melanoma.
PG  - 1146-56
LID - 10.1097/PAS.0b013e3181a1ef36 [doi]
AB  - Although the clinical and pathologic diagnosis of some melanomas is clear-cut, 
      there are many histopathologic simulators of melanoma that pose problems. 
      Over-diagnosis of melanoma can lead to inappropriate therapy and psychologic 
      burdens, whereas under-diagnosis can lead to inadequate treatment of a deadly 
      cancer. We used existing data on DNA copy number alterations in melanoma to 
      assemble panels of fluorescence in situ hybridization (FISH) probes suitable for 
      the analysis of paraffin-embedded tissue. Using FISH data from a training set of 
      301 tumors, we established a discriminatory algorithm and validated it on an 
      independent set of 169 unequivocal nevi and melanomas as well as 27 cases with 
      ambiguous pathology, for which we had long-term follow-up data. An 
      algorithm-using signal counts from a combination of 4 probes targeting chromosome 
      6p25, 6 centromere, 6q23, and 11q13 provided the highest diagnostic 
      discrimination. This algorithm correctly classified melanoma with 86.7% 
      sensitivity and 95.4% specificity in the validation cohort. The test also 
      correctly identified as melanoma all 6 of 6 cases with ambiguous pathology that 
      later metastasized. There was a significant difference in the metastasis free 
      survival between test-positive and negative cases with ambiguous pathology 
      (P=0.003). Sufficient chromosomal alterations are present in melanoma that a 
      limited panel of FISH probes can distinguish most melanomas from most nevi, 
      providing useful diagnostic information in cases that cannot be classified 
      reliably by current methods. As a diagnostic aid to traditional histologic 
      evaluation, this assay can have significant clinical impact and improve 
      classification of melanocytic neoplasms with conflicting morphologic criteria.
FAU - Gerami, Pedram
AU  - Gerami P
AD  - Department of Dermatology and the Lurie Cancer Center, Northwestern University, 
      The Feinberg School of Medicine University of California, San Francisco, CA, USA.
FAU - Jewell, Susan S
AU  - Jewell SS
FAU - Morrison, Larry E
AU  - Morrison LE
FAU - Blondin, Beth
AU  - Blondin B
FAU - Schulz, John
AU  - Schulz J
FAU - Ruffalo, Teresa
AU  - Ruffalo T
FAU - Matushek, Paul 4th
AU  - Matushek P 4th
FAU - Legator, Mona
AU  - Legator M
FAU - Jacobson, Kristine
AU  - Jacobson K
FAU - Dalton, Scott R
AU  - Dalton SR
FAU - Charzan, Susan
AU  - Charzan S
FAU - Kolaitis, Nicholas A
AU  - Kolaitis NA
FAU - Guitart, Joan
AU  - Guitart J
FAU - Lertsbarapa, Terakeith
AU  - Lertsbarapa T
FAU - Boone, Susan
AU  - Boone S
FAU - LeBoit, Philip E
AU  - LeBoit PE
FAU - Bastian, Boris C
AU  - Bastian BC
LA  - eng
GR  - R01 CA131524/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
RN  - 0 (Biomarkers, Tumor)
SB  - IM
EIN - Am J Surg Pathol. 2010 May;34(5):688
MH  - Adolescent
MH  - Adult
MH  - Algorithms
MH  - Biomarkers, Tumor/*genetics
MH  - Child
MH  - Female
MH  - Gene Dosage
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Melanoma/classification/*diagnosis/*genetics
MH  - Nevus, Epithelioid and Spindle Cell/diagnosis/genetics
MH  - ROC Curve
MH  - Sensitivity and Specificity
MH  - Skin Neoplasms/*classification/*diagnosis/genetics
EDAT- 2009/06/30 09:00
MHDA- 2009/08/19 09:00
CRDT- 2009/06/30 09:00
PHST- 2009/06/30 09:00 [entrez]
PHST- 2009/06/30 09:00 [pubmed]
PHST- 2009/08/19 09:00 [medline]
AID - 10.1097/PAS.0b013e3181a1ef36 [doi]
PST - ppublish
SO  - Am J Surg Pathol. 2009 Aug;33(8):1146-56. doi: 10.1097/PAS.0b013e3181a1ef36.